



October 4, 2022

BSE Limited
Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (Listing Regulations).**

We are pleased to enclose a Press Release as regards, receipt of U.S. FDA approval for the Company's Abbreviated New Drug Application for Darunavir Tablets, 600 mg and 800 mg, a generic equivalent of Prezista® Tablets of Janssen Products, LP.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**Rajvardhan
Vishnu Satam**

Digitally signed by Rajvardhan Vishnu Satam
DN: cn=, o=Maharashtra,
2.5.4.20=c19d8ef961d9fa59e973a093akd3924b2532eb2f496ea7e2
abc747005375b7, postalCode=400104, street=2404,SEJAL
TOWER,SEJAL PARK,LINK ROAD,GOREGAON WEST,Mumbai,Motilal
Nagar,Borivali,Mumbai Suburban,
pseudoym=9e4b7cd219ea516ad56e6d651dcbb5b, title=0191,
serialNumber=officetofa88c796663c738ea25a0b475d195726cd
b67a2ff09c4242771b2a, o=Personal, cn=Rajvardhan Vishnu Satam
Date: 2022.10.04 12:11:57 +05'30'

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl: a/a

Lupin Receives Approval from U.S. FDA for Darunavir Tablets

Mumbai, Baltimore, October 4, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Darunavir Tablets, 600 mg and 800 mg, a generic equivalent of Prezista® Tablets of Janssen Products, LP. Lupin is the exclusive first filer for 800 mg tablets and is eligible for 180-day exclusivity. Lupin will also potentially have shared 180-day exclusivity on the 600 mg tablets. The product will be manufactured at Lupin's facility in Nagpur, India.

Darunavir Tablets, 600 mg and 800 mg, (RLD Prezista®) had estimated annual sales of USD 343 million in the U.S. (IQVIA MAT June 2022).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

For further information or queries please contact –

Shweta Munjal

Vice President & Global Head – Corporate Communications

Email: shwetamunjal@lupin.com

***Safe Harbor Statement**

Prezista® is a registered trademark of Janssen Sciences Ireland Unlimited Company